Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 9/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.37 |
| ▸ | PDE1A | P54750 | 5/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25378663 | 0.86 | PDE1C (0.39) | PDE1CPDE1BPDE1A | |
| SCHEMBL23217412 | 0.85 | PDE1C (0.42) | PDE1CPDE1BPDE1A | |
| SCHEMBL12006092 | 0.85 | PDE1C (0.32) | PDE1CPDE1BPDE1A | |
| SCHEMBL401226 | 0.85 | PDE1C (0.33) | PDE1CPDE1BPDE1A | |
| SCHEMBL400651 | 0.83 | PDE1C (0.43) | PDE1CPDE1BPDE1A | |
| SCHEMBL18099738 | 0.81 | PDE1C (0.46) | PDE1CPDE1BPDE1A | |
| SCHEMBL2326369 | 0.80 | PDE1C (0.36) | PDE1CPDE1BPDE1A | |
| SCHEMBL14536725 | 0.79 | TNK2 (0.35) | PDE1CPDE1BPDE1A | |
| SCHEMBL21091174 | 0.79 | PDE1C (0.33) | PDE1CPDE1BPDE1A | |
| SCHEMBL19264176 | 0.79 | PDE1C (0.33) | PDE1CPDE1BPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
| EP-2325186-B1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007067709-A1 | PROCESS TO PREPARE SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067709-A1 | PROCESS TO PREPARE SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129547-A1 | Process to prepare substituted imidazopyrazine compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129547-A1 | Process to prepare substituted imidazopyrazine compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129547-A1 | Process to prepare substituted imidazopyrazine compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129547-A1 | Process to prepare substituted imidazopyrazine compounds | ZYX, BRPF3, NBAS | PDE1C 4008/4885PDE1B 4213/4885PDE1A 4534/4885 |
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | PDE1C 1830/4885PDE1B 1977/4885PDE1A 1718/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | PDE1C 2818/4885PDE1B 2739/4885PDE1A 2808/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | PDE1C 4285/4885PDE1B 3807/4885PDE1A 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.